{
    "clinical_study": {
        "@rank": "58616", 
        "arm_group": {
            "arm_group_label": "Cohort"
        }, 
        "brief_summary": {
            "textblock": "This observational study will evaluate the efficacy and safety of Pegasys (peginterferon\n      alfa-2a) in patients with chronic hepatitis B who have failed antiviral treatment with\n      nucleoside (nucleotide) analogues. Data will be collected from patients treated according to\n      the current Summary of Product Characteristics and local standard of care and regulations\n      during 48 weeks of treatment and 24 weeks of follow-up."
        }, 
        "brief_title": "An Observational Study of Pegasys (Peginterferon Alfa-2a) in Patients With Chronic Hepatitis B Who Have Failed Antiviral Treatment With Nucleoside (Nucleotide) Analogues", 
        "completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "condition": "Hepatitis B, Chronic", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis B", 
                "Hepatitis, Chronic", 
                "Hepatitis B, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Adult patients, >/= 18 years of age\n\n          -  Positive HBsAg for more than 6 months before assignment to treatment with Pegasys\n\n          -  Detectable HBV DNA (as measured by PCR)\n\n          -  HBeAg positive and negative patients\n\n          -  Patients previously treated with nucleoside (nucleotide) analogues who have failed\n             antiviral treatment and have been assigned to treatment with Pegasys according to the\n             local therapeutic standard\n\n          -  Elevated serum alanine aminotransferase (ALT)\n\n          -  Chronic hepatitis B confirmed by liver biopsy or non-invasive assessment (FibroScan),\n             ARFI, FibroTest) or by clinical evaluation\n\n        Exclusion Criteria:\n\n          -  Contraindications to treatment with Pegasys according to the Summary of Product\n             Characteristics\n\n          -  Hepatocellular carcinoma and/or severe hepatic dysfunction or decompensated cirrhosis\n             of the liver\n\n          -  Immunosuppression, immunomodulatory or chemotherapy within the last 6 months prior to\n             start of Pegasys treatment\n\n          -  Planned other than Pegasys antiviral treatment during Pegasys therapy\n\n          -  Chronic liver disease other than chronic hepatitis B\n\n          -  Pregnant or breast-feeding women\n\n          -  Inadequate hematologic function\n\n          -  Autoimmunology disorders\n\n          -  Co-infection with chronic hepatitis C or HIV"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Patients with chronic hepatitis B initiated on therapy with Pegasys"
            }
        }, 
        "enrollment": {
            "#text": "44", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 15, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01794234", 
            "org_study_id": "ML28346"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Peginterferon alfa-2a", 
                "Interferon-alpha"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 5, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Bytom", 
                        "country": "Poland", 
                        "zip": "41-902"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Debica", 
                        "country": "Poland", 
                        "zip": "39-200"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Gdansk", 
                        "country": "Poland", 
                        "zip": "80-214"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "31-202"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Krakow", 
                        "country": "Poland", 
                        "zip": "30-501"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lancut", 
                        "country": "Poland", 
                        "zip": "37-100"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Myslowice", 
                        "country": "Poland", 
                        "zip": "41-400"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Raciborz", 
                        "country": "Poland", 
                        "zip": "47-400"
                    }
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Wroclaw", 
                        "country": "Poland", 
                        "zip": "51-149"
                    }
                }
            }
        ], 
        "location_countries": {
            "country": "Poland"
        }, 
        "number_of_groups": "1", 
        "official_title": "Efficacy and Safety of Peginterferon Alfa-2a (40 KD) in Chronic Hepatitis B Patients, Who Have Failed Anti-viral Treatment With Nucleoside (Nucleotide) Analogues - an Observational Study in Real-life Clinical Practice", 
        "overall_official": {
            "affiliation": "Hoffmann-La Roche", 
            "last_name": "Clinical Trials", 
            "role": "Study Director"
        }, 
        "overall_status": "Terminated", 
        "oversight_info": {
            "authority": "Poland: Office for Registration of Medicinal Products, Medical Devices and Biocidal Products"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "September 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Efficacy: HBsAg seroclearance/seroconversion rate at the end of Week 72 (48 weeks of treatment and 24 weeks of follow-up)", 
            "safety_issue": "No", 
            "time_frame": "approximately 2.5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01794234"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "HBs levels in correlation with treatment outcome", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "For HBeAg positive patients: Proportion of patients with HBeAg loss and presence of anti HBe (HBeAg seroconversion) at the end of Week 72 (48 weeks of treatment and 24 weeks of follow-up)", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "For HBeAg negative patients: Proportion of patients with HBV DNA </= 2000 IU/ml and ALT normalization", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }, 
            {
                "measure": "Safety: Incidence of adverse events", 
                "safety_issue": "No", 
                "time_frame": "approximately 2.5 years"
            }
        ], 
        "source": "Hoffmann-La Roche", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Hoffmann-La Roche", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2012", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}